JFJuliette Foucher

Juliette Foucher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juliette Foucher has a total of 252 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ALSUntangled #84 – ivermectin

    by Benjamin Helmold, Carmel Armon, Michael Benatar, Tulio Bertorini, Mark Bromberg, Andrew Brown, Javier Mascias Cadavid, Olimpia Carbunar, Gregory T. Carter, Jesse Crayle, et al.

  • Open Access

    Muscle proteins in plasma associate to distinguished phenotypes in amyotrophic lateral sclerosis

    by Louisa Azizi, Inci S. Aksoylu, María Bueno Álvez, Juliette Foucher, Alexander Juto, Christina Seitz, Raymond Press, Kristin Samuelsson, Ulf Kläppe, Mathias Uhlén, et al.

    Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by death of upper and lower motor neurons, usually presented with clinical heterogeneity. Fluid biomarker development remains dominated by neurofilament light chain (NEFL), a marker of neuroaxonal injury. NEFL is however unspecific to ALS and its phenotypes and there is currently a lack of biomarkers that capture ALS heterogeneity such as onset site and ALS-frontotemporal spectrum disorder (ALS-FTSD). Therefore, we investigated whether plasma proteomics could reveal pathway-level signatures that stratify and explain ALS heterogeneity. Methods: We profiled ∼5,400 plasma proteins (Olink Explore HT) in 299 patients with ALS and 50 age- and sex comparable healthy controls. We used two complementary analytic frameworks: (i) differential protein abundance analysis to identify altered proteins in ALS and across clinical subgroups, and (ii) weighted gene correlation network analysis (WGCNA) to identify coordinated protein modules and relate them to ALS diagnosis and to ALS-specific clinical traits (site of onset, ALS-FTSD, ALS functional rating scale-revised (ALSFRS-R) score, and plasma NEFL). Results: Differential abundance analysis identified 56 proteins altered in ALS versus controls, of which 40 were increased. WGCNA identified 11 co-expression modules, with ALS samples having the strongest correlation to a protein module (n=51) highly enriched for muscle-related proteins. Out of the 40 proteins that had increased expression levels, 29 overlapped with the muscle-enriched protein module, indicating that muscle related proteins are the dominant circulating proteomic signature in ALS. This signal extended to clinical stratification: spinal-onset patients showed a strong positive association with the muscle-module. Further, differential abundance analysis of spinal- versus bulbar-onset ALS identified changes that mapped predominantly to the same module, supporting a molecular signature of onset phenotype. In contrast, cognitive status (ALS-FTSD) mapped to distinct modules enriched for extracellular matrix/cell-adhesion pathways, consistent with a separable biological axis of disease heterogeneity. Although multiple modules correlated with NEFL, trait-specific signatures were not fully explained by neuroaxonal injury. Notably, the muscle-enriched module increased with higher NEFL and lower ALSFRS-R, supporting its interpretation as a severity-linked, muscle-involvement proxy. Conclusions: Large-scale plasma proteomics reveals that heterogeneity in ALS reflects underlying biological structures. We identified a dominant muscle-associated protein network that distinguished ALS patients from controls and correlated with disease onset phenotype and severity, alongside distinct protein networks linked to ALS-FTSD. By integrating differential protein abundance with network-based analysis, we defined pathway-level biomarker signatures that extend beyond NEFL, enabling biologically informed patient stratification and improved therapeutic monitoring.


  • ALS untangled #83: clenbuterol

    by Adam Burgess, Olivia Allen, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Robert Bowser, Javier Mascias Cadavid, Gregory T Carter, Merit Cudkowicz, et al.

    ALS Untangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review clenbuterol, a β-2 adrenergic agonist, as a potential treatment for amyotrophic lateral sclerosis (ALS). Clenbuterol has biological effects that could be relevant to the pathophysiology of ALS such as inducing muscle hypertrophy, improving mitochondrial function, and reducing neuroinflammation. Two studies in mouse models of motor neuron disease and two open label trials suggest possible benefits. However these have methodological flaws which limit interpretation. Clenbuterol can have an array of side effects, some severe. Drop-outs due to side effects were very common in one of the ALS trials and in a separate expanded access program. Based on this information, we cannot currently endorse clenbuterol as an ALS treatment, but we do hope to see further studies of it, or another long acting β-2 adrenergic agonist in people with ALS.

  • Open Access

    Prioritizing neuropsychological research and care in Amyotrophic Lateral Sclerosis (ALS): building an international neuropsychological framework for ALS

    by Joke De Vocht, Emmet Costello, Caroline McHutchison, Ratko Radakovic, Juliette Foucher, Roisin McMackin, Colm Peelo, Leonard van Den Berg, Orla Hardiman, Philip Van Damme, et al.


  • Support vector machine classification of 18F-FDG PET scans across subtypes of amyotrophic lateral sclerosis

    by Chunmeng Tang, Juliette Foucher, Linn Öijerstedt, Fouke Ombelet, Caroline Ingre, Philip Van Damme, Koen Van Laere, Joke De Vocht, Michel Koole

    Purpose While 18F-FDG PET imaging has demonstrated diagnostic value in people with Amyotrophic Lateral Sclerosis (PwALS) and group-level differences were identified between different disease subtypes (e.g., genetic and clinical variants), refining and validating a machine-learning-based subject-level diagnostic algorithm may improve the general applicability and reliability of 18F-FDG PET as a diagnostic tool in ALS. In this study, we employed support vector machines (SVM) to further explore the diagnostic potential of 18F-FDG PET in ALS, alongside its ability to classify between different genetic subtypes or clinical phenotypes. Methods 18F-FDG PET data of 36 healthy volunteers (HV), 25 people with ALS-mimicking diseases (Mimics), and 167 PwALS, grouped by genetic status (e.g., sporadic (sALS) or carrying a C9orf72 hexanucleotide repeat expansion (ALSC9orf72RE) and onset (bulbar or spinal) type, acquired with Biograph ‘TruePoint’ PET/CT scanner, were included in the study (Dataset 1). A second dataset of 183 PwALS and 31 Mimics acquired with Biograph ‘HiRez’ scanner was included as an independent cross-validation set (Dataset 2). PET images were spatially normalised to MNI space to fit linear SVMs with cross-validation. Only age-matched groups were considered to eliminate age-related effects. Results For Dataset 1, the linear SVM resulted in an average accuracy of 0.86 for the classification of ALS vs. HV, 0.53 for ALS vs. Mimics, 0.83 for ALSC9orf72RE vs. sALS, and 0.58 for bulbar vs. spinal onset. These findings were corroborated with Dataset2, with an accuracy of up to 0.76 for ALSC9orf72RE vs. sALS, and 0.59 for bulbar vs. spinal. Conclusion 18F-FDG brain PET imaging, combined with SVM and age-matching, can distinguish between ALSC9orf72RE and sALS with good accuracy, but lacks sufficient discriminative power to differentiate between ALS and Mimics and between different sites of onset.


  • ALSUntangled #80: ISRIB (Integrated stress response InhiBitor)

    by Javier Mascias Cadavid, Anna Mena Bravo, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Sarah Breevoort, Andrew Brown, Gregory T. Carter, Jesse Crayle, Juliette Foucher, et al.

    ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we assess ISRIB, a molecule that attenuates the integrated stress response (ISR). The ISR is an intracellular signaling network through which cells normally respond to stress, but in ALS it appears to be overactive, leading to the formation of "stress granules" which some but not all investigators believe can triggerapoptotic cell death. ISRIB can attenuate the formation of these stress granules while still allowing parts of protein synthesis to continue. Pre-clinical data demonstrate that ISRIB is beneficial in cell models of ALS. A small number of patients taking ISRIB in Spain report symptomatic improvements with little or no side effects, though we have not been able to independently verify these benefits. There are no clinical trials evaluating ISRIB in any condition and questions about its solubility and bioavailability have arisen. Currently, we do not have enough evidence to endorse the use of ISRIB for treating ALS. We support further research in disease models and clinical trials to study pharmacokinetics, safety and efficacy.


  • Open Access

    Venous Bicarbonate as a Prognostic Biomarker and Proposed Proxy for Vital Capacity to Be Used as an Eligibility Criterion in Amyotrophic Lateral Sclerosis Clinical Trials

    by Juliette Foucher, Therese Wellander, Anikó Lovik, Linn Öijerstedt, Alexander Juto, Fang Fang, Caroline Ingre

    Background: Clinical trials for people living with ALS (pALS) all list vital capacity (VC) as an important eligibility criterion. However, VC measures are challenging to perform among pALS, especially bulbar pALS. Additionally, since the disease rapidly changes, the VC can change in a short duration of time, making it unreliable.Objective: We aimed to investigate the association of venous bicarbonate with VC as an alternative criterion for trial eligibility. We also wanted to examine whether venous bicarbonate could be used as a prognostic biomarker for survival in ALS.Methods: We included pALS from the Swedish ALS/MND Registry between January 1, 2019 and July 31, 2022. pALS had to have serum bicarbonate values and ALSFRS‐R available close to diagnosis. Spearman correlations, Kaplan–Meier curves, and Cox proportional hazard regressions were used to assess the associations of venous bicarbonate with VC, other clinical characteristics, and survival.Results: Among the 117 pALS included in the study, we observed a negative correlation between venous bicarbonate and VC among spinal and bulbar pALS (ρ = −0.346, p = 0.002 and ρ = −0.367, p = 0.024, respectively). Venous bicarbonate negatively correlated with ALSFRS‐R (ρ = −0.377, p < 0.001), specifically among bulbar pALS (ρ = −0.595, p < 0.001), but positively correlated with KING's stage (ρ = 0.248, p = 0.007). High level of venous bicarbonate appeared to be associated with shorter survival.Conclusions: Venous bicarbonate appears to be a prognostic biomarker for survival among pALS. This cheap and easily accessible measure could potentially be an alternative for VC as an eligibility criterion in ALS trials.


  • Open Access

    Minimum clinically important difference for drug effectiveness in an area of patient-oriented therapeutic goals in amyotrophic lateral sclerosis

    by Adriano Chiò, Juliette Foucher, Kelly G Gwathmey, Caroline Ingre

    Objective: In this review, we will examine the more common endpoints incorporated in randomized controlled trials (RCTs) and their strength of evidence, focusing on the definition of what constitutes a clinically meaningful change. We will also reflect on the perspective of patients and their families regarding the design of RCTs in amyotrophic lateral sclerosis (ALS). Methods: Authors performed a scoping review of the literature around clinical meaningfulness in the ALS field and the minimum clinically important difference to deem a treatment effective. Results: The use of survival as an RCT endpoint, as well as the ALS functional rating scale-revised slope, has been criticized, and their relevance for patients remains debated. Biomarkers are promising alternatives as surrogate endpoints, but currently, only cerebrospinal fluid and plasma neurofilaments have emerged as reliable and sensitive biomarkers of disease progression. Incorporating patients' preferences and priorities for their care when treatments are selected is important to minimize the burden of care and limit the potential harms of overtreatment. Patients' interest in and acceptance of a new therapy is also determined by its impact on their quality of life. Discussion and conclusion: While scientifically sound trials must be conducted, this must be balanced with patient expectations of limiting trial burden, duration and placebo usage. An important approach in uniting these diverging needs is the inclusion of people with ALS and their organizations to advise in the design and execution of clinical trials, facilitating the design of RCTs more focused on patients' expectations while retaining a high scientific rigor.


  • Open Access

    From cognitive and behavioral impairment to clinical trial inclusion, for an inclusive approach of amyotrophic lateral sclerosis

    by Juliette Foucher

    ALS is a fatal and rapidly progressing neurodegenerative disease where the death of motor neurons results in the paresis of skeletal muscles and ultimately death from respiratory failure within 2 to 5 years. As no cures are currently available, people living with ALS (pALS) rely on clinical trials. However, the design of ALS trials does not always reflect the vast heterogeneity of the disease. Most pALS with behavioral or cognitive impairment are excluded from ALS trials, and many patients with bulbar ALS are struggling to perform some tests including in trial screening visits. In this thesis, we aimed to characterize cognitive and/or behavioral impairment of pALS in Sweden and use our findings as a stepping- stone to investigate clinical trial inclusiveness in a broader sense, with a focus on pre-screening and screening.In Study I, we conducted a systematic review on the use of population and disease registries for clinical trial pre-screening. Our goal with this study was to set the stage for what is currently done and learn from previous research. Therefore, we did not limit our search to the ALS field but included all publications from 2014 to 2022 reporting registry use of trial pre-screening. We found that during that timeframe, only 24 studies clearly reported such use despite obvious benefits being stated such as time efficiency of the pre-screening time and economic benefits. Pre-screening strategies being under-reported in the scientific literature, more population or disease registries may be used in a trial recruitment setting, however it seems like the clinical trial world is heavily relying on recruitment registries specifically designed for trial recruitment purposes.In Study II, we aimed to validate the Swedish version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS), a screening tool for cognitive impairment. We found that the Swedish version of the ECAS was a valid and reliable tool to use, which led us to investigate cognition of pALS longitudinally, using the ECAS in Study III. We found that cognition was stable in pALS during the first 2 years following the ALS diagnosis, and we identified 3 main clusters of cognitive impairment profiles.In Study IV, we aimed to translate and implement the dimensional apathy scale (DAS) in Swedish within our cohort, characterize the apathy levels of pALS and investigate their longitudinal apathy levels. We found that the DAS was reliable to use in Swedish, that emotional and executive apathy levels were stable during the first year following the ALS diagnosis, but we did not observe a statistically significant relationship between apathy levels and clinical trial interest.Finally in Study V, we investigated venous bicarbonate as a potential proxy to vital capacity as a trial eligibility criterion. We found that venous bicarbonate was able to predict survival. Moreover, venous bicarbonate concentrations over 26 mmol/L were associated with higher risks of death for pALS.In summary, cognitive impairment and apathy levels in Swedish pALS were characterized in this thesis. Additional studies are required to investigate potential apathy clusters or profiles in pALS, as well as discriminative predictors for trial participation and considerations.List of scientific papersI. Foucher, J., Azizi, L., Öijerstedt, L., Kläppe, U., & Ingre, C. (2024). The usage of population and disease registries as pre-screening tools for clinical trials, a systematic review. Systematic Reviews, 13(1), 111. https://doi.org/10.1186/s13643-024-02533-0II. Foucher, J., Winroth, I., Lovik, A., Sennfält, S., Pereira, J. B., Fang, F., Lule, D., Andersen, P. M., & Ingre, C. (2023). Validity and reliability measures of the Swedish Karolinska version of the Edinburgh Cognitive and Behavioral ALS Screen (SK-ECAS). Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 1-6. Advance online publication. https://doi.org/10.1080/21678421.2023.2239857III. Öijerstedt, L., Foucher, J., Lovik, A., Yazdani, S., Juto, A., Kläppe, U., Fang, F., & Ingre, C. (2024). Repeated cognitive assessments show stable function over time in patients with ALS. Journal of Neurology, 271(8), 5267-5274. https://doi.org/10.1007/s00415-024-12479-xIV. Foucher, J., Lovik, A., Öijerstedt, L., Radakovic, R., Fang, F. & Ingre, C. Longitudinal apathy measures show stability of executive and emotional apathy levels but no association between apathy levels and clinical trial interest. [Manuscript]V. Foucher, J .* , Wellander, T .* , Lovik, A., Öijerstedt, L., Juto, A., Fang, F., & Ingre, C. Venous bicarbonate, a proposed proxy for vital capacity to be used as an eligibility criterion in amyotrophic lateral sclerosis clinical trials. [Submitted]* Equal contribution

  • Open Access

    From cognitive and behavioral impairment to clinical trial inclusion, for an inclusive approach of amyotrophic lateral sclerosis

    by Juliette Foucher

    ALS is a fatal and rapidly progressing neurodegenerative disease where the death of motor neurons results in the paresis of skeletal muscles and ultimately death from respiratory failure within 2 to 5 years. As no cures are currently available, people living with ALS (pALS) rely on clinical trials. However, the design of ALS trials does not always reflect the vast heterogeneity of the disease. Most pALS with behavioral or cognitive impairment are excluded from ALS trials, and many patients with bulbar ALS are struggling to perform some tests including in trial screening visits. In this thesis, we aimed to characterize cognitive and/or behavioral impairment of pALS in Sweden and use our findings as a stepping- stone to investigate clinical trial inclusiveness in a broader sense, with a focus on pre-screening and screening.In Study I, we conducted a systematic review on the use of population and disease registries for clinical trial pre-screening. Our goal with this study was to set the stage for what is currently done and learn from previous research. Therefore, we did not limit our search to the ALS field but included all publications from 2014 to 2022 reporting registry use of trial pre-screening. We found that during that timeframe, only 24 studies clearly reported such use despite obvious benefits being stated such as time efficiency of the pre-screening time and economic benefits. Pre-screening strategies being under-reported in the scientific literature, more population or disease registries may be used in a trial recruitment setting, however it seems like the clinical trial world is heavily relying on recruitment registries specifically designed for trial recruitment purposes.In Study II, we aimed to validate the Swedish version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS), a screening tool for cognitive impairment. We found that the Swedish version of the ECAS was a valid and reliable tool to use, which led us to investigate cognition of pALS longitudinally, using the ECAS in Study III. We found that cognition was stable in pALS during the first 2 years following the ALS diagnosis, and we identified 3 main clusters of cognitive impairment profiles.In Study IV, we aimed to translate and implement the dimensional apathy scale (DAS) in Swedish within our cohort, characterize the apathy levels of pALS and investigate their longitudinal apathy levels. We found that the DAS was reliable to use in Swedish, that emotional and executive apathy levels were stable during the first year following the ALS diagnosis, but we did not observe a statistically significant relationship between apathy levels and clinical trial interest.Finally in Study V, we investigated venous bicarbonate as a potential proxy to vital capacity as a trial eligibility criterion. We found that venous bicarbonate was able to predict survival. Moreover, venous bicarbonate concentrations over 26 mmol/L were associated with higher risks of death for pALS.In summary, cognitive impairment and apathy levels in Swedish pALS were characterized in this thesis. Additional studies are required to investigate potential apathy clusters or profiles in pALS, as well as discriminative predictors for trial participation and considerations.List of scientific papersI. Foucher, J., Azizi, L., Öijerstedt, L., Kläppe, U., & Ingre, C. (2024). The usage of population and disease registries as pre-screening tools for clinical trials, a systematic review. Systematic Reviews, 13(1), 111. https://doi.org/10.1186/s13643-024-02533-0II. Foucher, J., Winroth, I., Lovik, A., Sennfält, S., Pereira, J. B., Fang, F., Lule, D., Andersen, P. M., & Ingre, C. (2023). Validity and reliability measures of the Swedish Karolinska version of the Edinburgh Cognitive and Behavioral ALS Screen (SK-ECAS). Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 1-6. Advance online publication. https://doi.org/10.1080/21678421.2023.2239857III. Öijerstedt, L., Foucher, J., Lovik, A., Yazdani, S., Juto, A., Kläppe, U., Fang, F., & Ingre, C. (2024). Repeated cognitive assessments show stable function over time in patients with ALS. Journal of Neurology, 271(8), 5267-5274. https://doi.org/10.1007/s00415-024-12479-xIV. Foucher, J., Lovik, A., Öijerstedt, L., Radakovic, R., Fang, F. & Ingre, C. Longitudinal apathy measures show stability of executive and emotional apathy levels but no association between apathy levels and clinical trial interest. [Manuscript]V. Foucher, J .* , Wellander, T .* , Lovik, A., Öijerstedt, L., Juto, A., Fang, F., & Ingre, C. Venous bicarbonate, a proposed proxy for vital capacity to be used as an eligibility criterion in amyotrophic lateral sclerosis clinical trials. [Submitted]* Equal contribution